CoChat
Sign Up
Cited by 1Hemophilia Treatment and ResearchPlatelet Disorders and TreatmentsCoagulation, Bradykinin, Polyphosphates, and Angioedema

Saudi expert consensus on acquired hemophilia A diagnosis and management

Open access
Almomen, Abdulkareem M., Alzahrani, Hazza A., AlSaeed, Hussein H., AlAseri, Zohair, Mady, Ahmed F., Owaidah, Tarek·2024·Journal of Taibah University Medical Sciences
DOI 10.1016/j.jtumed.2024.04.006PMC PMC11087233
Open this paper in CoChat — free account

Abstract

Objectives: Acquired hemophilia affects approximately one in 1 million people. Timely diagnosis is key to appropriate disease management and the prevention of life-threatening complications. Patients with this condition may initially be seen by inexperienced physicians and remain underdiagnosed for several years. This consensus statement is aimed at providing guidelines for all practitioners in the Kingdom of Saudi Arabia (KSA) to diagnose and manage acquired hemophilia A. Methods: This consensus statement reflects the opinions drafted by a group of hematology specialists, who used an explicit systematic process to identify areas of agreement and disagreement. Results: This consensus statement provides a guide for all practitioners in the KSA regarding the diagnosis of clinical presentation, relevance, characteristics of bleeding symptoms, and case management; it additionally provides guidance for non-specialists. All management aspects, including diagnosis and treatment modalities, are discussed. Conclusions: Patients with acquired hemophilia may initially be seen by physicians who lack appropriate expertise in diagnosing and managing this condition. This consensus statement from the premier experts on the disease in the KSA provides details for diagnosing and managing acquired hemophilia.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jtumed.2024.04.006

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Biodegradable polymeric nanoparticles tend to degrade and clear faster, reducing the risk of long-term accumulation.

    “In contrast, biodegradable polymeric NPs tend to degrade and clear faster, reducing the risk of long-term accumulation [178].”

    From Targeted Nanoparticles for Drug Delivery Across the Blood–Brain Barrier in Early and Late Stages of Alzheimer's Disease: A Review (2026) · cites this paper as [178]

    The Management > Treatment of bleeding episodes and Management > Eradication of inhibitors sections discuss acquired hemophilia A therapies, not nanoparticles. Searches for biodegradable polymeric nanoparticles, clearance, and long-term accumulation found no passage addressing the claim in our copy; page numbers were not available. (LLM, conf=0.78)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 33 · Cited by 1

Research works printed but not linked: 33

  1. [1]Sholzberg M. Hemostatic abnormalities in the critically ill. Hematologic challenges in the critically ill 2018 Springer 17 39
  2. [2]Mazzucconi M.G. Baldacci E. Ferretti A. Santoro C. Acquired haemophilia A: an intriguing disease Mediterranean J Hematol Infect Dis 12 1 2020 PMC7340240 32670523
  3. [3]Soucie J.M. Le B. Dupervil B. Poston J.N. Prevalence of comorbid conditions among older males with haemophilia receiving care in haemophilia treatment centers in the United States Haemophilia 28 6 2022 986 995 35924815 PMC10591247
  4. [4]Itzhar-Baikian N. Boisseau P. Joly B. Veyradier A. Updated overview on von Willebrand disease: focus on the interest of genotyping Expert Rev Hematol 12 12 2019 1023 1036 31536379
  5. [5]Tiede A. Wahler S. The rising incidence of acquired haemophilia A in Germany Haemophilia 27 4 2021 e466 e468 32937680
  6. [6]Franchini M. Vaglio S. Marano G. Mengoli C. Gentili S. Pupella S. Acquired hemophilia A: a review of recent data and new therapeutic options Hematology 22 9 2017 514 520 28441921
  7. [7]Tiede A. Collins P. Knoebl P. Teitel J. Kessler C. Shima M. International recommendations on the diagnosis and treatment of acquired hemophilia A Haematologica 105 7 2020 1791 1801 32381574 PMC7327664
  8. [8]Tiede A. Collins P. Knoebl P. Teitel J. Kessler C. Shima M. International recommendations on the diagnosis and treatment of acquired hemophilia A Haematologica 105 7 2020 1791 32381574 PMC7327664
  9. [9]Charlebois J. Rivard G.-É. St-Louis J. Management of acquired hemophilia A: review of current evidence Transfus Apher Sci 57 6 2018 717 720 30396835
  10. [10]Poon M.-C. The use of recombinant activated factor VII in patients with Glanzmann's thrombasthenia Thromb Haemostasis 121 3 2021 332 340 33124022 PMC7895543
  11. [11]Amano K. Seita I. Higasa S. Sawada A. Kuwahara M. Shima M. Treatment of acute bleeding in acquired haemophilia A with recombinant activated factor VII: analysis of 10-year Japanese postmarketing surveillance data Haemophilia 23 1 2017 50 58 27457022
  12. [12]Kitazawa T. Igawa T. Sampei Z. Muto A. Kojima T. Soeda T. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model Nat Med 18 10 2012 1570 1574 23023498
  13. [13]Donners A.A. Rademaker C.M. Bevers L.A. Huitema A.D. Schutgens R.E. Egberts T.C. Pharmacokinetics and associated efficacy of emicizumab in humans: a systematic review Clin Pharmacokinet 60 11 2021 1395 1406 34389928 PMC8585815
  14. [14]Kizilocak H. Marquez-Casas E. Malvar J. Carmona R. Young G. Determining the approximate factor VIII level of patients with severe haemophilia A on emicizumab using in vivo global haemostasis assays Haemophilia 27 5 2021 730 735 34115433
  15. [15]Young G. Liesner R. Chang T. Sidonio Jr R. Oldenburg J. Jiménez-Yuste V. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors Blood, The Journal of the American Society of Hematology 134 24 2019 2127 2138 PMC6908828 31697801
  16. [16]Mahlangu J. Iorio A. Kenet G. Emicizumab state-of-the-art update Haemophilia 28 2022 103 110 35521723 PMC9321850
  17. [17]Belletrutti M. Bhatt M. Samji N. Management of children with hemophilia A on emicizumab who need surgery Front Pediatr 11 2023 1155853 PMC10110896 37082707
  18. [18]Kruse-Jarres R. Kempton C.L. Baudo F. Collins P.W. Knoebl P. Leissinger C.A. Acquired hemophilia A: updated review of evidence and treatment guidance Am J Hematol 92 7 2017 695 705 28470674
  19. [19]Remmington T. Smith S. Rituximab for eradicating inhibitors in people with acquired haemophilia A Cochrane Database Syst Rev 8 2021 PMC8407509 34423414
  20. [20]Jiang L. Liu Y. Zhang L. Santoro C. Rodriguez A. Rituximab for treating inhibitors in people with inherited severe hemophilia Cochrane Database Syst Rev 8 2020 PMC8407108 32761818
  21. [21]Franchini M. Rituximab in the treatment of adult acquired hemophilia A: a systematic review Crit Rev Oncol Hematol 63 1 2007 47 52 17236786
  22. [22]Arruda V.R. Lillicrap D. Herzog R.W. Immune complications and their management in inherited and acquired bleeding disorders Blood J Am Soc Hematol 140 10 2022 1075 1085 PMC9461471 35793465
  23. [23]Mingot-Castellano M.E. Rodríguez-Martorell F.J. Nuñez-Vázquez R.J. Marco P. Acquired haemophilia A: a review of what we know Hematol Res Rev 13 2022 691 710 PMC9701517 36447782
  24. [25]Franchini M. Schiavulli M. Liumbruno G.M. Hemostatic therapy as a management strategy for acquired hemophilia: what does the future hold? Expert Rev Hematol 14 3 2021 263 270 33655810
  25. [26]Schünemann H.J. Cushman M. Burnett A.E. Kahn S.R. Beyer-Westendorf J. Spencer F.A. American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients Blood Adv 2 22 2018 3198 3225 30482763 PMC6258910
  26. [27]Bronić A. Coen Herak D. Margetić S. Milić M. Croatian Society of Medical Biochemistry and Laboratory Medicine: national recommendations for blood collection, processing, performance and reporting of results for coagulation screening assays prothrombin time, activated partial thromboplastin time, thrombin time, fibrinogen and D-dimer Biochem Med (Zagreb) 29 2 2019 020503 PMC6559624 31223257
  27. [28]Toulon P. Metge S. Hangard M. Zwahlen S. Piaulenne S. Besson V. Impact of different storage times at room temperature of unspun citrated blood samples on routine coagulation tests results. Results of a bicenter study and review of the literature Int J Lab Hematol. 39 5 2017 458 468 28481034
  28. [29]Lima-Oliveira G. Brennan-Bourdon L. Varela B. Arredondo M. Aranda E. Flores S. Clot activators and anticoagulant additives for blood collection. A critical review on behalf of COLABIOCLI WG-PRE-LATAM Crit Rev Clin Lab Sci 58 3 2021 207 224 33929278
  29. [30]Ovanesov M.V. Jackson J.W. Golding B. Lee T.K. Considerations on activity assay discrepancies in factor VIII and factor IX products J Thromb Haemostasis 19 9 2021 2102 2111 34145730
  30. [31]Moore G. Peyrafitte M. Dunois C. Amiral J. Newly developed dilute Russell's viper venom reagents for lupus anticoagulant detection with improved specificity Lupus 27 1 2018 95 104 28549386
  31. [32]Novembrino C. Boscolo Anzoletti M. Mancuso M.E. Shinohara S. Peyvandi F. Evaluation of an automated chromogenic assay for Factor VIII clotting activity measurement in patients affected by haemophilia A Haemophilia 25 3 2019 521 526 31044485
  32. [33]Kaneda M. Kawasaki R. Matsumoto N. Abe H. Tashiro Y. Inokuchi Y. Detailed analysis of anti-emicizumab antibody decreasing drug efficacy, using plasma samples from a patient with hemophilia A J Thromb Haemostasis 19 12 2021 2938 2946 34418287 PMC9292660
  33. [34]Chansavang A. Philippe A. Bozinovic I. Ben Hadj Ali K. Smadja D. Helley D. Usefulness of anti-factor VIII IgG ELISA in acquired hemophilia A follow-up Ann Hematol 101 11 2022 2453 2460 36125542

Authors
Almomen, A. M., Alzahrani, H. A., AlSaeed, H. H., AlAseri, Z., Mady, A. F., & Owaidah, T.
Affiliations
  • King Saud University (SA)
  • Alfaisal University (SA)
Corresponding author
Owaidah, Tarek
ORCID
Venue
Journal of Taibah University Medical Sciences
Publisher
Elsevier BV
Published
2024-06
Volume
19
Issue
3
Pages
566-574
ISSN
1658-3612 (ISSN-L)
DOI
10.1016/j.jtumed.2024.04.006
PMC
PMC11087233
OpenAlex
W4395697203
Cited by
1
References
33
Citations by year
2025: 1
FWCI
0.31
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Taibah University Medical Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
Novo Nordisk AS
Topics
  • Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
  • Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
  • Health Sciences › Medicine › Genetics › Coagulation, Bradykinin, Polyphosphates, and Angioedema
Keywords
acquired hemophilia A, diagnosis, management, bleeding manifestations, clinical features, treatment options, underdiagnosis, Saudi Arabia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review